NCT04048343View on ClinicalTrials.gov

Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma

PHASE3CompletedINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

June 10, 2019

Primary Completion Date

March 18, 2021

Study Completion Date

March 18, 2021

Conditions

Severe Asthma

Interventions

DRUG

Biological: Experimental: Tezepelumab

Tezepelumab subcutaneous injection every 4 weeks

Trial Locations (5)

103-0022

Research Site, Chūōku

104-0031

Research Site, Chūōku

228-0815

Research Site, Sagamihara-shi

140-8522

Research Site, Shinagawa-ku

169-0073

Research Site, Shinjuku-ku

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

AstraZeneca

INDUSTRY